TAK vs. NUTX

Last updated Apr 1, 2026

Compare and contrast key facts about Takeda Pharmaceutical Company Limited (TAK) and Nutex Health Inc (NUTX).

Performance

TAK vs. NUTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Takeda Pharmaceutical Company Limited (TAK) and Nutex Health Inc (NUTX). The values are adjusted to include any dividend payments, if applicable.

TAK vs. NUTX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
TAK Takeda Pharmaceutical Company Limited	18.79%	23.18%	-3.12%	-4.87%	8.50%
NUTX Nutex Health Inc	-42.27%	419.47%	17.37%	-90.53%	-95.25%

Fundamentals

EPS TAK : $36.10 NUTX : $14.78
PE Ratio TAK : 0.51 NUTX : 6.43
PS Ratio TAK : 0.01 NUTX : 0.47
Total Revenue (TTM) TAK : $4.49T NUTX : $875.26M
Gross Profit (TTM) TAK : $2.79T NUTX : $444.28M
EBITDA (TTM) TAK : $1.39T NUTX : $274.31M

Returns By Period

In the year-to-date period, TAK achieves a 18.79% return, which is significantly higher than NUTX's -42.27% return.

TAK

• 1D: 1.37%
• 1M: -1.23%
• YTD: 18.79%
• 6M: 26.50%
• 1Y: 27.35%
• 3Y*: 7.79%
• 5Y*: 3.44%
• 10Y*: 1.65%

NUTX

• 1D: 4.55%
• 1M: -13.96%
• YTD: -42.27%
• 6M: -8.01%
• 1Y: 102.08%
• 3Y*: -14.40%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

TAK vs. NUTX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TAK

TAK Risk / Return Rank: 78
TAK Sharpe Ratio Rank: 81
TAK Sortino Ratio Rank: 74
TAK Omega Ratio Rank: 73
TAK Calmar Ratio Rank: 80
TAK Martin Ratio Rank: 80

NUTX

NUTX Risk / Return Rank: 72
NUTX Sharpe Ratio Rank: 72
NUTX Sortino Ratio Rank: 79
NUTX Omega Ratio Rank: 74
NUTX Calmar Ratio Rank: 72
NUTX Martin Ratio Rank: 64

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TAK vs. NUTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Takeda Pharmaceutical Company Limited (TAK) and Nutex Health Inc (NUTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	TAK	NUTX	Difference
Sharpe ratio Return per unit of total volatility	1.30	0.88	+0.41
Sortino ratio Return per unit of downside risk	1.76	1.99	-0.23
Omega ratio Gain probability vs. loss probability	1.23	1.24	-0.01
Calmar ratio Return relative to maximum drawdown	2.24	1.54	+0.69
Martin ratio Return relative to average drawdown	5.82	2.40	+3.41
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

TAK vs. NUTX - Sharpe Ratio Comparison

The current TAK Sharpe Ratio is 1.30, which is higher than the NUTX Sharpe Ratio of 0.88. The chart below compares the historical Sharpe Ratios of TAK and NUTX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	TAK	NUTX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.30	0.88	+0.41
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.18	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.07	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.12	-0.48	+0.60

Correlation

The correlation between TAK and NUTX is 0.05, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

TAK vs. NUTX - Dividend Comparison

TAK's dividend yield for the trailing twelve months is around 1.74%, while NUTX has not paid dividends to shareholders.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
TAK Takeda Pharmaceutical Company Limited	1.74%	4.24%	4.67%	4.41%	4.23%	2.98%	2.30%	4.20%	4.77%	2.81%	3.99%	2.92%
NUTX Nutex Health Inc	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Drawdowns

TAK vs. NUTX - Drawdown Comparison

The maximum TAK drawdown since its inception was -54.25%, smaller than the maximum NUTX drawdown of -99.93%. Use the drawdown chart below to compare losses from any high point for TAK and NUTX.

Drawdown Indicators

	TAK	NUTX	Difference
Max Drawdown Largest peak-to-trough decline	-54.25%	-99.93%	+45.68%
Max Drawdown (1Y) Largest decline over 1 year	-12.83%	-54.34%	+41.51%
Max Drawdown (5Y) Largest decline over 5 years	-30.09%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-54.25%	—	—
Current Drawdown Current decline from peak	-18.51%	-98.42%	+79.91%
Average Drawdown Average peak-to-trough decline	-23.22%	-97.24%	+74.02%
Ulcer Index Depth and duration of drawdowns from previous peaks	4.94%	34.90%	-29.96%

Volatility

TAK vs. NUTX - Volatility Comparison

The current volatility for Takeda Pharmaceutical Company Limited (TAK) is 6.63%, while Nutex Health Inc (NUTX) has a volatility of 24.94%. This indicates that TAK experiences smaller price fluctuations and is considered to be less risky than NUTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	TAK	NUTX	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.63%	24.94%	-18.31%
Volatility (6M) Calculated over the trailing 6-month period	13.96%	73.87%	-59.91%
Volatility (1Y) Calculated over the trailing 1-year period	21.17%	116.41%	-95.24%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	19.34%	135.16%	-115.82%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	23.02%	135.16%	-112.14%

Financials

TAK vs. NUTX - Profitability Comparison

The chart below illustrates the profitability comparison between Takeda Pharmaceutical Company Limited and Nutex Health Inc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

TAK - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Takeda Pharmaceutical Company Limited reported a gross profit of 660.35B and revenue of 1.21T. Therefore, the gross margin over that period was 54.4%.

NUTX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Nutex Health Inc reported a gross profit of 46.14M and revenue of 151.68M. Therefore, the gross margin over that period was 30.4%.

TAK - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Takeda Pharmaceutical Company Limited reported an operating income of 194.06B and revenue of 1.21T, resulting in an operating margin of 16.0%.

NUTX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Nutex Health Inc reported an operating income of 39.37M and revenue of 151.68M, resulting in an operating margin of 26.0%.

TAK - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Takeda Pharmaceutical Company Limited reported a net income of 105.51B and revenue of 1.21T, resulting in a net margin of 8.7%.

NUTX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Nutex Health Inc reported a net income of 11.83M and revenue of 151.68M, resulting in a net margin of 7.8%.